European Medicines Agency validates application for nivolumab combined with chemotherapy as first-line treatment in metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma

Filing is based on CheckMate -649 trial, in which treatment with nivolumab plus leucovorin, 5-FU and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CapeOX) vs. chemotherapy alone resulted in statistically significant improvement in overall- and progression-free survival.

Biospace Inc.